Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes

J. S. Westerdahl; K. B. Nusbaum; C. G. Chung; B. H. Kaffenberger; A. G. Ortega-Loayza

doi:10.1080/09546634.2021.1937475

Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes

J. S. Westerdahl, K. B. Nusbaum, C. G. Chung, B. H. Kaffenberger, A. G. Ortega-Loayza

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	2386-2390
Number of pages	5
Journal	Journal of Dermatological Treatment
Volume	33
Issue number	4
DOIs	https://doi.org/10.1080/09546634.2021.1937475
State	Published - 2022

ASJC Scopus subject areas

Dermatology

Access to Document

10.1080/09546634.2021.1937475

Cite this

@article{42345dcc60334460bc5070a12e141dae,

title = "Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes",

author = "Westerdahl, {J. S.} and Nusbaum, {K. B.} and Chung, {C. G.} and Kaffenberger, {B. H.} and Ortega-Loayza, {A. G.}",

year = "2022",

doi = "10.1080/09546634.2021.1937475",

language = "English (US)",

volume = "33",

pages = "2386--2390",

journal = "Journal of Dermatological Treatment",

issn = "0954-6634",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes

AU - Westerdahl, J. S.

AU - Nusbaum, K. B.

AU - Chung, C. G.

AU - Kaffenberger, B. H.

AU - Ortega-Loayza, A. G.

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85107841423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107841423&partnerID=8YFLogxK

U2 - 10.1080/09546634.2021.1937475

DO - 10.1080/09546634.2021.1937475

M3 - Letter

C2 - 34057010

AN - SCOPUS:85107841423

SN - 0954-6634

VL - 33

SP - 2386

EP - 2390

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

IS - 4

ER -

Ustekinumab as adjuvant treatment for all pyoderma gangrenosum subtypes

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this